Monday, December 8, 11:00 AM
3002-3004 - West (Moscone Center)
"Inhibition of Syk Activity is Sufficient for Inhibitory Effect in Animal Models of Autoimmune Diseases" (abstract # 680)
Monday, December 8, 5:15 PM 2006-2008 - West (Moscone Center) Factor Xa Inhibitor Antidote
"Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors" (abstract # 983)
Saturday, December 6, 5:30 PM Hall A (Moscone Center)
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current treatments for cardiovascular and inflammatory diseases and cancer.
Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi- billion dollar antithrombotic market. Both product candidates have best-in- class features versus current and novel agents in development and address the hospital, specialty, and chronic care markets. The Company's earlier-stage programs are leveraging its chemistry capability to develop specific Syk and JAK inhibitors to treat cancer and inflammatory diseases. The company also has a novel Factor Xa inhibitor antidote program with the potential to help manage the more than 20 million patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit http://www.portola.com.
Contact: Mardi Dier - CFO, Portola Pharmaceuticals 650-246-7236 firstname.lastname@example.org Julie Normart, Invigorate Communications 415-946-1087 '/>"/>
|SOURCE Portola Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved